This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shankar, G., Pendley, C. & Stein, K.E. Nat. Biotechnol. 25, 555–561 (2007).
European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins EMEA/CHMP/BMWP/14327/2006. <http://www.emea.europa.eu/htms/human/humanguidelines/multidiscipline.htm>
BMWP/BWP Workshop on Immunogenicity Assessment of Therapeutic Proteins, EMEA, London, September 4, 2007. <http://www.emea.europa.eu/meetings/conferences/4sep07.htm>
European Medicines Agency. European Public Assessment Report (EPAR) for Remicade. <http://www.emea.europa.eu/humandocs/Humans/EPAR/remicade/remicade.htm>
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.K.S. is chairman of the CHMP Working Party on Similar Biological (Biosimilar) Medicinal Products Working Party (BMWP) and P.K. is a former chairman of BMWP. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the EMEA or one of its committees or working parties.
Rights and permissions
About this article
Cite this article
Schneider, C., Papaluca, M. & Kurki, P. A European perspective on immunogenicity evaluation. Nat Biotechnol 27, 507–508 (2009). https://doi.org/10.1038/nbt0609-507
Issue Date:
DOI: https://doi.org/10.1038/nbt0609-507
This article is cited by
-
Strategies and challenges for the next generation of therapeutic antibodies
Nature Reviews Immunology (2010)